key: cord-0792763-y93xc9eo authors: Mehta, Meenu; Satija, Saurabh; Paudel, Keshav R; Liu, Gang; Chellappan, Dinesh K; Hansbro, Philip M; Dua, Kamal title: Incipient need of targeting airway remodeling using advanced drug delivery in chronic respiratory diseases date: 2020-04-30 journal: Future medicinal chemistry DOI: 10.4155/fmc-2020-0091 sha: 38496078ba8550f7f2dd5991b5744b79a248d5a3 doc_id: 792763 cord_uid: y93xc9eo nan Commentary Mehta, Satija, Paudel et al. bronchial portions and subsegmental walls have their whole dimensions thickened [8] . In COPD, only the inner wall of the major airways is thicker and more persuasive. The peripheral airways are often distinctly remodeled in COPD, typically free of cartilage or bronchial tissue [9, 10] . Like most airway remodeling, transient airflow obstructions, caused by inflammation, mucus spikes and bronchial hyper-reactiveness are associated with CRDs, for instance. Given the present care and management choices, a substantial number of patients remain poorly managed for such diseases, namely, asthma and COPD, which are usually triggered by a respiratory virus infection. As a result, new innovative drug therapies remain important in order that exacerbations can be better managed and avoided. Thus, various advanced therapies have been developed in the field of drug delivery in respiratory diseases such as nanoparticles (NPs), including extracellular vesicles and their synthetic equivalents [11] . Ideally, these new therapeutic strategies are focused on the activation of the regenerative capacity of the lung itself. Understanding the various pathways and the targeted delivery of drugs that initiate, sustain, modulate, and conclude normal lung development could be essential to new regenerative approaches by reactivating pulmonary disease pathways [12] . Targeted advanced drug-delivery strategies can provide increased accumulation, greater effectiveness and enhanced protection. Gabriela et al. recently coupled an anti-fibrotic small molecule (αPV1) with an anti-PV1 antibody and reported a substantial reduction in lung fibrosis in idiopathic pulmonary fibrosis, compared with an isotype controlled antibody [13] . Juan et al. made ATG101 single-stranded antisense RNA-loaded DNA triangular NPs (ssATG101-TNP) to knock down expression of the ATG101 gene. They demonstrated that ssATG101-TNP can efficiently be transfected into human pulmonary arterial endothelial cells in a time and dose-dependent manner, and knockdown of ATG101 stimulates the cell apoptosis and inhibits hypoxic cell autophagy and proliferation as a possible therapeutic goal for endothelial injury related conditions [14] . In scleroderma associated interstitial lung disease (SSc-ILD), patients with derived cells in an experimental lung fibrosis model, were administered with imatinib loaded gold nanoparticles (GNPs). GNPs were synthesized using anti-CD44 and were loaded with imatinib (GNP-HCIm). Patients with scleroderma associated interstitial lung disease were diagnosed with lung fibroblast and alveolar macrophages in the presence of NPs from bronchoalveolar lavage fluids. Their research showed that the GNP-HCIm significantly inhibited proliferation and viability inducing apoptosis of LFs and effectively reduced IL-8 release, viability and M2 polarization in alveolar macrophages. [15] . Tsai et al. reported that cerium dioxide NPs can reduce Ca 2+ cytosolic change and TiO 2 NP-induced mitochondrial damage. Their team presented evidence that TiO 2 NPs can attenuate hypersecretion and apoptosis progression [16] . In a most recent study conducted by Chattopadhyay et al., atropine nanoparticles (ANPs) have been shown to suppress inflammatory cytokines, reduce shallow breathing and normalize the hyper-responsiveness of the tidal tissue and obstructed lungs. Moreover, treatment with ANP reduced progressive blockage of the airway and decreased deposition of collagens. Thus, ANP strengthens the airway surfaces of the lung and reduces lung hyperaction, blockage and inflammation [17] . Lou et al. showed the significance of miRNA in airway remodeling. It was shown that miR-192-5p had an overexpressed effect in the smooth muscle cells in airways. In addition, in vitro and in vivo asthma mice demonstrated a similar effect which was shown to be the effect of miR-192-5p on proliferation [18] . Prior to this, various other studies have also reported the potential of miRNA in tissue regeneration. Simeoli et al. in their research showed that the delivery of LNA-based anti-miR21 and anti-miR-712 in mouse models of atherosclerosis and nerve trauma reduced the inflammatory macrophage number through liposomes or cationic lipids-coated NPs [19, 20] . All of these evidences in one way or other, state that the combinations of the different targeted approach contribute to the drug research and development for airway tissue regeneration. Advancements in the field of drug delivery, particularly NPs, is providing an extra edge in combating the emerging complications of airway remodeling in chronic respiratory diseases. Considering the fact that remodeling worsens the respiratory disease pathology, it is an emerging and demanding area of research to be explored by translational, clinical and drug-delivery scientists to provide a new direction to the pulmonary clinics especially during the current, complex and uncertain times of global pandemic situation. Global initiative for asthma: Asthma management and prevention 2019 Interactions with the macrophages: an emerging targeted approach using novel drug delivery systems in respiratory diseases Oligonucleotide therapy: an emerging focus area for drug delivery in chronic inflammatory respiratory diseases Airway remodeling in chronic obstructive pulmonary disease and asthma: the role of matrix metalloproteinase-9 Airway remodeling in asthma Novel concepts in airway inflammation and remodeling in asthma The immune basis of allergic lung disease Airway remodeling in COPD: it's not asthma Upper and lower airway remodeling mechanisms in asthma, allergic rhinitis and chronic rhinosinusitis: the one airway concept revisited. Allergy Eur Airway remodeling in asthma: what really matters Emerging trends in the novel drug delivery approaches for the treatment of lung cancer Inhalable nanotherapeutics to improve treatment efficacy for common lung diseases Targeted drug delivery via caveolae-associated protein PV1 improves lung fibrosis ATG101 single-stranded antisense RNA-loaded triangular DNA nanoparticles control human pulmonary endothelial growth via regulation of cell macroautophagy Imatinib-loaded gold nanoparticles inhibit proliferation of fibroblasts and macrophages from systemic sclerosis patients and ameliorate experimental bleomycin-induced lung fibrosis CeO 2 nanoparticles attenuate airway mucus secretion induced by TiO 2 nanoparticles Synthesized atropine nanoparticles ameliorate airway hyperreactivity and remodeling in a murine model of chronic asthma MiRNA-192-5p attenuates airway remodeling and autophagy in asthma by targeting MMP-16 and ATG7 Multifunctional nanoparticles facilitate molecular targeting and miRNA delivery to inhibit atherosclerosis in ApoE-/-mice Exosomal cargo including microRNA regulates sensory neuron to macrophage communication after nerve trauma